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able total and low-density lipaprotsin cholesterol evels to be less than 200 
and 160 mg/dl, respectively, for healthy individuals without multiple coronary 
risk factors, Coronary heart disease risk, however, decreases at lower levels. 
To determine whether those levels are vascular biologically desirable, we as- 
sessed flow-mediated (endothelium-dependsnt) bn3chial artery vasoactivity 
nontnvasively before, during, and following cholesterol owering (simvastaUn 
10 mg/dw) in 7 healthy, middle-aged men, Flow-mediated brachlal artery 
vasoactivfty was measured using 7.5 MHz ultrasound and expressed as % 
diameter change from baseline to hyperemio conditions (1 minute following 5 
minutes of blood pressure cuff arterial occlusion). Row-mediated vosoactivify 
rose from 5.0 4. 3.6% at baseline tO 10.5 4, 5.6, 13.3 :E 4.3 and 15.7 4- 4.9% 
(all p < 0.05) as cholesterol fell from 200:1:12 to 161 -I- 18, 169 4- 16, and 
153 4- t 1 mg/di after 2. 4 and 12 weeks, respectively, of cholesterol lowering 
therapy. Vascacttvlty and cholesterol returned to baseline levels 12 weeks 
after simvastatin discontinuation. Overall, vasoacttvity was found to correlate 
Inversely with cholesterol levels (r = -0.47, p = 0.004). Those data suggest 
that flow-mediated brachial artery vasoactivity mspands rapidly to changes in 
cholesterol evels and that vascular biologically desirable cholesterol levels 
may be lower than these recommended by current guidelines for healthy, 
mlddle-aged men. 
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2:00 
~7-~-~ Thrombolysis With Samplase Is at Least as 
Effective in AMI as Stmptokinase: COMPASS 
Double-Bl ind Study in 3089 Patients 
Ulrich Tabbe, Roll' Michels, Jennifer Adgey, Amadeu Betdu, Abraham Cespi, 
Bernard Charbonnier, William Fennell, Mikhail Ruda, Johannes Mlczoch, 
Jean Boland, Ricardo Seabre-Gomes, JOrgen Windeler, Robert Groves, 
Gwyn Hopkins, Hannes Berth for the COMPASS Study Group. Detmold, 
Germany 
Samplese (BAR) restores patency quicker than straptokinase (SK) in AMI 
pats. (PRIMI ~'tudy). To show equivalence in 30 d mortality rates in this study, 
AMI pats. with < 6 h symptoms were mndomised to SAR (20 mg bolus, 60 
mg/I h; heparin iv bolus 5000 IU before) or SK (1.5 x 10 s lUll h) between 8/92 
and 7/94. Aspirin pa and heparin iv for > 24th were routine. 104 hospitals 
in 10 West European countries Israel and Russia entered 3089 pats. (3088 
evaluable, > 99.9%). 
Results SAR SK Absol. 95% C.I. 
(n = 1542) (n = 1547) diff. 
30 d mortality 88 (5.7%) 104 (6.7%) -1.0% -2.8 to 0,8 
--cardiac related o 69 (4.5%) 94(6,1%) -1.90/= -3.2to 0.0 
-involving stroke ° 13 (0.8%) 10 (0.6%) 0.2% -0.5 to 0.9 
Stnokes (to d 12) 19 (1.2%) 17(1.1%) 0.1% -0.7to 1.0 
-hemorrhagic 11 (0.7%) 4 (0.3%) 0.5% -0.1 to 1.0 
-- thrombo-embolic 5 {0.3%) 12 (0,8%) -0.50/,, -1.0tO 0.1 
-undassif. (no CT) 3 (0.2%) 1 (0.1%) 0.1% -0,2 to 0.4 
30 d mortality or 90 (5.8%) 107 (6.9%) -1.1% -2.9 to 0.7 
disabtin 0stroke 
°not mutually exclusive 
Conclusions:30 day mortality rates show that SAR is as least as efficacious 
as SK (p < 0.001; test for equivalence: OR < 1.5). Overall stroke rates 
are similar, but may differ for different etiologies. Combining (all cause) 30 
d mortality and disabling stroke suggests that the apparent advantage of 
sarupJase therapy is maintained, 
2:15 
~High  Hospital Mortality Despite a Frequent Use of 
Thrombolysis in Acute Myocerdlal Infarction 
J. Rustige, R, $chlele, U. Burczyk, A. Koch 1 U. Tebbe 2, J. Senges for the 
ALKK Study Group. Hetzzentrum Ludwigshafen, Cardiology, Germany; 
r ZMBT Heidelberg, Germany; 2 Klinikum Lippe-Detmold, Germany 
"The 60-Minutes Myocardial Infarction Project" is a German multi-center 
study to reduce prehospltal delay (PHD) and a,d increase the rate of throm- 
bolysis in AMI, This paper evaluates the routine use of drugs in the early 
treatment and the hospital mortality of AMI. 
Methods: From 7/92 to 9/94 all pts with transmural AMI presenting within 
the first 96 hours in 136 hospitals were registered (n = 14,980, mean age 68 
4, 13 yrs, 68% male, 45"/0 anterior wall MI, 19% ralnfarctions). PHD delay, 
treatment regimen, early and total mortality were documented. 
Results: 1. Thrombolysis was g:van in 53% of pts with AMI; of these, 66% 
received streptokinase, 18% rt-PA and 9% urokinase. 2, Eady mortality in 
the coronary care unit (48 h) was 7.6%, 3. Total hospital mortality (22 d) was 
17.2%. 4, Median PHD was 2.8 h, 16.7°/,, of pts arrived within 1 h after onset 
of symptoms (hospital mortality 15.1%). 4. Use of early medical treatment 
Lyals rate within the first hour after onset of symptoms was 78%, after 12 h 
PHO 11.8%. In a logistic regression model strong predictors for thrombolysis 
were diagnostic ECG, cardlogenic shock and male gender. 
Drugs,_ Thrombotytlcs ,8-blocker ASS Heparin 
Frequency 53% 160/o 81% 8P/o 
Conclusions: In Germany more than half of the pts with transmural AMI 
are treated with thrombctytics, the majority of pts still receive strepfoklnase. 
2. Mortality Is twice as high as reported in randomized megatrials because 
no pts were excluded. 3. Betablocker therapy is given in a minority of pts 
despite ist documented benefit. 
2:30 
~3"~ Low Molecular Weight H~parin (Fragmln ®) In Acute 
Myocardial Infarction 
Frederic Kontny, Jon Dale, Ulrich Abildgaard, Terje Pedersen for the FRAMI 
Study Group. Aker University Hospital, University of Oslo, Oslo, Norway 
The objective of the trial was to study the efficacy and safety of Fragmin ® 
(Pharmacia, Sweden) in prevention of left ventricular thrombus (LVT) for- 
mation and artedal embolism (AE) after acute antedor myocardial infarction 
(AMI). The trial design was placebo-controlled, randomised, double-blind and 
mulUcentral. Fragmin ® (150 IU/kg BW b.i.d.) was given until pre-diecharge 
echocardiogrsphy (2DE) at day 9 -=- 2. The 2DE recordings were centrally 
evaluated. AE, reinfarction, mortality and haemorrhagos were recorded con- 
tinuously throughout hospitalisation, Only aspidn was allowed as adjunctive 
antithrombotic treatment. 
Results: 776 patients were randomised in the trial. Streptoktnase and 
aspirin were given to > 90 percent of the patients. Other important concomi. 
rant treatment as well as baseline characteristics did not differ between the 
groups. The results are based on intention-to-treat analyses. 
Endpoint Fragrntn ® Placebo P 
LVT 13.3% 21.9% 0,022 
AE 1.8% 1.4% ns 
Reinfarcfion 1.9% 2.2% ns 
Mortality 5.9% 5.9% ns 
Major bleeding 2.90/0 0.3% 0.006 
Conclusions: Fregmin ® was associated with a significant reduction in LVT 
formation after AML The numbers of arterial embolism and reinfarctions were 
low with no difference between the treatment groups. Furthermore, them was 
no diffemnca in mortality rates between the groups. However, Fregmin ® was 
associated with a signiticant increase in major bleeding. 
2:45 
~ Differences in Outcome After Angioplssty for Acute 
Myocardial Infarction: The Left Anterior Descending 
Artery vs. the Right Coronary Artery 
Barry M. Kaplan, Robert D. Safian, Cindy L, Grines, Venu M. Reddy, William 
W. O'Neill. William Beaumont Hospital, Royal Oak, Michigan 
A comparison of left anterior descending (LAD, n = 232) and right coronary 
(RCA, n = 227) angioplesty (PTCA) in a group of 459 consecutive patients 
presenting with myocardial infarction to our institution was performed. Sev- 
enteen (7.4%) patients In each group had thrombolytlc failure (p = NS), 
LAD RCA p value 
Procedural Events 
Bradyarrhythmlas 2 (0.8%) 19 (8.4°/=) <0.0001 
Defibrillation 4 (1.'P/o) 13 (5.7%) <0.02 
Major dissection 6 (2,6%) 8 (3.5%) NS 
Persistent thrombus or no-rell0w 10 (4.3%) 20 (8.8%) <0,05 
Major angiographlc events 17(7,3%) 31 (13.7%) <0.03 
Clinical Events 
Abrupt Closure 16 (6.9%) 17 (7.50/,) NS 
Bypass surgery 8 (3.40/,) 4 (1.80/o) NS 
Mortality wilhout shock 6 (3%) 3 (1.50/,) NS 
Cardlogenic shock mortality 19/33 (57.80/0) 7/31 (22,60/o) <0,005 
Total death 25 (10,80/=) 10 (4.4%) <0.01 
Major clinical events 42 (180/o) 22 (10%) <0.01 
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Cardiogenfc shock was present in 33 (14.2%) LAD and 31 (13.'P/o) RCA 
patients (p = NS). Major angiographio (major dissection, no-reflow, perfora- 
tion), and major clinical (abrupt closure, bypass surgery, death) events were 
reviewed. 
Conclusions: Despite similarities in baseline patient demographics, PTCA 
of the RCA was associated with more procedural complications than PTCA of 
the LAD, but this did not worsen in-hospital outcomes. Convemely, PTCA of 
the LAD was associated with an increase in major in-hospital cardiac events, 
mostly secondary to the risk of death in the presence of cardieganio shock. 
Therefore, when performing PTCA of the RCA, procedural details such as 
temporary pacing, defibrillation, intensive ant)coagulation, and management 
of no-raflow need to be considered. In contrast, for PTCA of the LAD, proce- 
dural complications are rare, but case selection and shock stgnHicantiy alter 
in-hospital outcome. 
3:00 
~"~ Prophy~ic Intmaortio Balloon Pumping for Acute 
Myocardial Infarction Does Not Improve Left 
Ventdeular Function 
Cindy L. Grines, Bruce R. Brodie, John J. Griffin, Bryan C, Donohue, 
C. Costantint, Carlos Bafastrinl, Gregg Stone, Thomas R Whadon, Jr., 
Uoudmila Mitina, Mar)ann Graham, Denise E, Jones, Dabra Sachs, William 
W. O'Neill, William Beaumont Hospital, Royal Oak, MI 
It has been suggested that the afterload reduction offered by inlraanrtic 
balloon counterpuisation 0ABP) may improve left ventricular performance or 
effect remodeling alter acute myocardial infarction. To investigate this issue, 
we randomized 437 high risk M110ts (age > 70, ejection fraction < 45%, 3 
vessel disease, suboptimal PTCA, SVG occlusion, ventricu'ar ant~thmlas) 
to receive or not receive IABP for 48 hours after- reperfusion with primap/ 
PTGA. Contrast left ventriculography was obtained acutely (prior to IABP) 
and repeated at 1 week. Radionuclide ventriculograpby was performed at 6 
weeks. 
Prophylactic IABP placement did not prevent hemedynamio deterioration 
as mffacted by in-hospital sustained hypetension, CHF, pulmonary edema, 
need for vasoprassom, or death. Furthermore, IABP did not influence global 
or legional LV function, as follows: 
LV Function IABP No IABP P 
El:: acute 46% 49% 0.01 
1 week improvement 1.4% 1.5% NS 
Infarct zone: acute -2.6 SD/Chord -2.6 SO/Chord NS 
1 week improvement 0.2 SD/Chord 0.3 SD/Chord NS 
EF: 6 week 48% 47% NS 
In conclusion, although IABP may be useful in treal/ng hemedynamic 
problems with AMI, prophylactic placement for 48 hrs does not prevent 
hemodynamic deterioration or influence left vantricular regional or global 
systolic function. 
3:15 
~ Simultaceous Glyceprotein Integdn Plate)st lib/Ills 
Blockade and Front-loaded Tissue Plasminogen 
Activator in Acute Myocardial infarction: Results 
From a Randomized Trial 
E. Magnus Ohman, Neat S, Klaiman, Gerald Gacloch, Seth Worlay, J. 
David Talley, Frank l. Nave))a, H. Vernon Anderson, Doug Spdggs, 
Michael Miller, Mark Cohen, Dean Kereiakas, Bany S. George, Kdstina 
N. Sigmon, Mitohell Krucoff, Robert M. Calitf, Eric J. Topoi far the 
IMPACT-AMI Group, Duke University, Durham, NC 
The platatet glycoprotain I(b/llla receptor blocker Integrslin in combination 
with accelerated tPA has been found to have a dose-dependant effect on 
ex-vivo piatelet aggregation. To evaluate the outcomes in tots with acute 
myocardial infarction receiving tPA, Integrelin, heparin, and aspidn, a double- 
blind randomized lrial was performed. After a dese-escalation phase an 
Integrafln dose of 180 ug/k0 bolus followed by 0.75 ug/kg infusion was 
selected and was sfudled in 51 pfa with 55 pts receiving placebo. Pts race)red 
a bolus within 10 rains of starling tPA and the infusion was continued for 24 
hours. All pts had 90 minute anglegmphy and 87 had 24-hour continuous ST 
segment monitoring. Pts allocated to lntegmlin had similar ates of severe 
Outcomes lntegmfln Placebo 
T1MI Grade 3 66% 39% 
Pelency (TIMI grade 2 + 3) 87% 69% 
Death 7.8% 3.6% 
tO Bleed 2% 0 
Reinfarction 0 3.6% 
CHF/Pulm edema 9.8% 7,3% 
p = O.Q06 
p = 0.01 
bleeding (4% vs 5%) ) and blood transfusions (16% vs 18%) compared with 
placebo 10is. Intagrelin treated pts had a shorter time to steady state (66 vs 
116 rains, p = 0.05), less recurrent iSchemia (31% vs 5(~,o, p = 0.t 3), and 
area under the ST curve during the first 6 hours (2868 vs 6670, p = 0.13) on 
ST monitoring. 
Conclusion: Potent platelet a~regation blockade using Integrelin during 
thrombolysis may be an attractive strategy to improve roper)us)on rates and 
reduce ischemia in acute myocardial infarction. 
I -~  Angiographle and Clinical Predictors of 
Outcome After Device Intervention 
Tuesday, March 26, 1995, 2:00 p.m.-3:30 p.m. 
Orange County Convention Center, Room 314 
2:00 
~ A  Mete-Analysb on the Clinical and Angiographic 
Outcomes of S tem vs PTCA in the Different 
Coronary V ~  in the Benestent.1 and Stress 1 
and 2 Trials 
Sheldon Gold'oerg, Aida J. Azar, Ferdinand Kiemonij, Peter de Jaegare, 
Richard Schatz, Donald Bairn, Martin Leon, Paldck W. Sen'uys. Cardialysis, 
Rotterdam; The Netherlands 
Both the Benestent and Stress 1 and 2 trials compared elective Palmaz- 
Schatz stent (St vs balloon angioplasty (PTCA) in denovo lesions. These 
trials demonstrated that S improve the angiographio and clinical outcomes. To 
determine the impact of S vs PTCA in reducing ~ clinical and angiographio 
events, we analysed the data according to lesion location. The results were 
as follows: 
LAD PTCA LAD S RCA RCA S LCX LCX S 
PTCA PTCA 
(n=293) (n=307} (n=176) (n=151) (n=54| (n=78) 
Event 101(34%) 75(24%) 44(25%) 25(17%) 12(22%) 16(21%) 
Pcuto gain 1.04 1.47 1.18 1.72 1.16 1.65 
Late loss 0.45 0.72 032 0.64 0.33 0.70 
Net gain 0.67 0.74 0.84 1.07 0.85 0.94 
Restenosis 110(43%) 74(27%) 45(32%) 30(23%) 15(32%) 18(25%) 
%0S FUP 48:1:18 42~19 42 d: 16 38:1:16 41+19 39±19 
MLD FUP 1.50 1.69 1.78 1.95 1.74 1.77 
Event, dead/mi/cabg/ptca; restenosis, > 50% d'mrneter stenosis follow-up; mid, minimal 
tureen diarmate~, %DS, diameter steno~s at fortow-up (FU). 
In all vessels, S achieved a better acute gain, net gain anti lower %OS 
as compared to PTCA. However, acute gain was the lowest in LAD, and 
therefore %DS post procedure the highest in LAD. Late loss was greater 
in the S Itrespec~ve of the vessel, with ~ highest late loss for the LAD. 
The restanosis rate was lower In S as cempared to PTCA but nevertheleas 
higher in the LAD. The event rate was lowast in the S gatients as compared 
to PTCA ~ ,  with the LAD yle~ng the highest event rate compared to 
RCA/LCX. 
Conclusion: a l~h S prey)de better a r~ io  and din)cat outcomes 
compared to PTCA, the risk of events and restenosis is more pronounced in 
the LAD when compared to RCA/LCX. 
2:15 
['7--'~-'-2-1 Predictors of late Mortality Following Ablative 
New-Device Angtopinsty In Native Coronary Arteries 
Simon R. Redwood, Jeffrey J. Popma, Kenneth M. Kent, Aegtmte 
D. Pichard, Loweg F. Satfar, Gary S. Mintz, Mun K. Hnog, Thamsa 
A. Buchar, Alan J. IVlarr~ Martin B. Leon. Washir~on ~-~ Center 
Washington, DC 
We have previously repoded that 'minor" CPK-MB elevation is associated 
increased late mortality fotlot~g aUath~ new-device angioldasty (NDA) 
in naive coronaries. To determina the iedepandent ~ and causes 
of late moflatity following NDA, we examined the course of lOtS treated 
w~th d~c~onal ae~ectemy (n = 554 lesions), reta~onal ae~ectomy (n 
= 833) and exdmer laser angioplasty (n = 510) between t/90 and 2/94. 
lot)awed for 353 -I- 46 days. The overafl ir~,-,ce of late enoC~ily was 
2.2%. Pt- and lesion-related factors were examined using multivariate logistlc 
regression analysis. Of all variables examined, only post-procedura cute 
renal failure (ARF) and CPK-MB elevation {minor:. > 1 and < 4X nml (ie., 5- 
16 eg/ml):, major > 4X nml (ie., > 17 ng/ml)} were found to be ;c~pc-,-dent 
precrctom of late mortality. Spedf'¢ NDA used was not an independent 
predictor. 
